Alternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

A University of Alberta research team has taken the first step toward proving its innovative gene therapy can successfully ...

Antisense oligonucleotide (ASO) technology has accelerated drug discovery in the last few decades with several ASO-based ...

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

Investigators in the laboratory of Gemma Carvill, Ph.D., assistant professor in the Ken and Ruth Davee Department of Neurology Division of Epilepsy/Clinical Neurophysiology, have discovered novel ...

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...

Gazyva/Gazyvaro is an anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a CRR benefit in lupus ...